Vitiligo Drugs Market Market Size Is Projected to Reach US$ 348.3 Million at a CAGR of 12.9% Till 2027

Vitiligo is a medical condition characterized by white patches on the skin and is also known as skin depigmentation. In skin depigmentation, the skin's pigment-making cells known as melanocytes are lost or destroyed, which results in patches. The patches of affected skin appear white and usually have sharp margins. Although the disease can occur at any age, it is more observed in the mid-twenties. The disease does not affect the physical health of a person, however, it creates concerns regarding physical appearance and ethical identity of the person.

The global vitiligo drug market size was valued at US$ 120.6 million in 2017 and is expected to exhibit a CAGR of 8.4% over the forecast period (2018–2026).

Growing prevalence and incidence of vitiligo is projected to augment the global vitiligo drugs market growth

Vitiligo causes loss of skin color in spots and can affect the skin on any part of the body, hair, and the inside of the mouth. Treatment for vitiligo can restore the color to the affected spot on the skin. However, it cannot completely prevent skin discoloration. According to the American Academy of Dermatology, 2017, the prevalence of vitiligo is approximately 1% in the U.S. and Europe.

𝐁𝐮𝐲 𝐍𝐨𝐰 𝐚𝐧𝐝 𝐆𝐞𝐭 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐅𝐅

𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐓𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐩𝐨𝐫𝐭 𝐓𝐨 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 @ https://www.coherentmarketinsights.com/promo/buynow/2447

Vitiligo is listed among 24 skin diseases examined in the Burden of Skin Disease report commissioned by the American Academy of Dermatology. Moreover, according to reports published by the American Academy of Dermatology in 2017, over 150,000 patient was treated for vitiligo during 2013 in the U.S. According to a study published in the National Center for Biotechnology Information (NCBI), in October 2017, an estimated 0.5-1% of the global population was diagnosed with vitiligo. Furthermore, in the same year, approximately 8.8% of India’s population and 0.38% of Denmark’s population was diagnosed with vitiligo.

Therefore, the growing prevalence of vitiligo around the globe is expected to support the growth of the global vitiligo drug market over the forecast period.

However, the availability of advanced technologies and alternative therapies for vitiligo treatment is projected to restrain the growth of the vitiligo drug market during the forecast period. For instance, in October 2018, STRATA Skin Sciences, a manufacturer of innovative products for the treatment of skin conditions, announced the launch of XTRAC S3 308nm Laser at the American Society for Dermatologic Surgery Meeting. The XTRAC S3 308nm Laser is used for the treatment of skin disorders such as psoriasis and vitiligo. The XTRAC laser utilizes therapeutic UVB light for the treatment of affected skin areas without damaging surrounding healthy skin.

A growing number of funding grants to accelerate the development of effective treatment for vitiligo is projected to foster the market growth

The rising number of initiatives undertaken by government organizations to develop novel treatments for vitiligo is projected to augment market growth. For instance, in February 2019, American Skin Association (ASA) announced funding for 18 new grants for skin cancer and disease research. The ASA and its affiliates invested over US$ 50 Mn for the treatment of melanoma, psoriasis, and vitiligo. Moreover, various government organizations are also focused on offering funds to accelerate the development of effective treatment options for vitiligo, thereby augmenting the market growth. For instance, the Vitiligo Society in Europe funds research projects to establish the real causes of vitiligo as well as develop effective and safe treatments for patients. The Society also supports and closely monitors research initiatives and is supported by a Medical and Scientific Advisory Panel.

𝐓𝐨 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐰𝐢𝐭𝐡 𝐋𝐚𝐭𝐞𝐬𝐭 𝐂𝐨𝐯𝐢𝐝𝟏𝟗 𝐈𝐦𝐩𝐚𝐜𝐭 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 @ https://www.coherentmarketinsights.com/insight/request-sample/2447

Key Players

Key players in the market are focused on adopting acquisition strategies to enhance their market share, which is expected to augment the market growth. For instance, in 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a company focused on the development of kinase inhibitors for the treatment of autoimmune disorders such as alopecia areata, vitiligo, and atopic dermatitis.

Major players operating in the global vitiligo drugs market include 𝗗𝗲𝗿𝗺𝗮𝘃𝗮𝗻𝘁 𝗦𝗰𝗶𝗲𝗻𝗰𝗲𝘀, 𝗜𝗻𝗰., 𝗜𝗻𝗰𝘆𝘁𝗲 𝗖𝗼𝗿𝗽𝗼𝗿𝗮𝘁𝗶𝗼𝗻, 𝗔𝗰𝗹𝗮𝗿𝗶𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝘀, 𝗜𝗻𝗰., 𝗗𝗿. 𝗥𝗲𝗱𝗱𝘆’𝘀 𝗟𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝗶𝗲𝘀 𝗟𝘁𝗱., 𝗕𝗿𝗶𝘀𝘁𝗼𝗹 - 𝗠𝘆𝗲𝗿𝘀 𝗦𝗾𝘂𝗶𝗯𝗯, 𝗣𝗳𝗶𝘇𝗲𝗿, 𝗜𝗻𝗰., 𝗖𝗹𝗶𝗻𝘂𝘃𝗲𝗹 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 𝗟𝘁𝗱., 𝗔𝗽𝗽𝗹𝗶𝗲𝗱 𝗕𝗶𝗼𝗹𝗼𝗴𝘆, 𝗜𝗻𝗰., 𝗮𝗻𝗱 𝗕𝗼𝘀𝘁𝗼𝗻 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀.

𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧:

• 𝐆𝐥𝐨𝐛𝐚𝐥 𝐕𝐢𝐭𝐢𝐥𝐢𝐠𝐨 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐁𝐲 𝐃𝐫𝐮𝐠 𝐓𝐲𝐩𝐞:

o Marketed Drugs
o Calcineurin Inhibitors
o Corticosteroids
o Psoralens
o Pipeline Drug
o Ruxolitinib (Phase 3)

• 𝐆𝐥𝐨𝐛𝐚𝐥 𝐕𝐢𝐭𝐢𝐥𝐢𝐠𝐨 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐁𝐲 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐓𝐲𝐩𝐞:

o Segmental Vitiligo
o Non-segmental Vitiligo

• 𝐆𝐥𝐨𝐛𝐚𝐥 𝐕𝐢𝐭𝐢𝐥𝐢𝐠𝐨 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐁𝐲 𝐑𝐨𝐮𝐭𝐞 𝐨𝐟 𝐀𝐝𝐦𝐢𝐧𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 𝐓𝐲𝐩𝐞:

o Oral
o Topical

• 𝐆𝐥𝐨𝐛𝐚𝐥 𝐕𝐢𝐭𝐢𝐥𝐢𝐠𝐨 𝐃𝐫𝐮𝐠 𝐌𝐚𝐫𝐤𝐞𝐭, 𝐁𝐲 𝐃𝐢𝐬𝐭𝐫𝐢𝐛𝐮𝐭𝐢𝐨𝐧 𝐂𝐡𝐚𝐧𝐧𝐞𝐥:

o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies

𝐓𝐨 𝐆𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @ https://www.coherentmarketinsights.com/insight/request-pdf/2447

Contact Us:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About US:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.